Legend new Carvykti® data in multiple myeloma, 1st-in-human results in CAR-T in non-Hodgkin

 

• Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI®
  
  
• Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey
  
  
• Eighty percent of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 months after a single infusion of CARVYKTI®
  
  
• Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma

https://www.globenewswire.com/news-release/2025/12/06/3201084/0/en/Legend-Biotech-Highlights-New-CARVYKTI-Data-in-Multiple-Myeloma-and-First-in-Human-Results-from-Novel-CAR-T-Platform-in-Non-Hodgkin-Lymphoma-at-ASH-2025.html